GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » EV-to-FCF

Aurobindo Pharma (NSE:AUROPHARMA) EV-to-FCF : (As of May. 15, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aurobindo Pharma's Enterprise Value is ₹676,844 Mil. Aurobindo Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₹0 Mil. Therefore, Aurobindo Pharma's EV-to-FCF for today is .

The historical rank and industry rank for Aurobindo Pharma's EV-to-FCF or its related term are showing as below:

NSE:AUROPHARMA' s EV-to-FCF Range Over the Past 10 Years
Min: -199.88   Med: 0   Max: 29.85
Current: -195.65

During the past 13 years, the highest EV-to-FCF of Aurobindo Pharma was 29.85. The lowest was -199.88. And the median was 0.00.

NSE:AUROPHARMA's EV-to-FCF is ranked worse than
100% of 518 companies
in the Drug Manufacturers industry
Industry Median: 24.625 vs NSE:AUROPHARMA: -195.65

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Aurobindo Pharma's stock price is ₹1168.60. Aurobindo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹47.250. Therefore, Aurobindo Pharma's PE Ratio for today is 24.73.


Aurobindo Pharma EV-to-FCF Historical Data

The historical data trend for Aurobindo Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma EV-to-FCF Chart

Aurobindo Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 555.02 9.38 35.29 16.39 -88.21

Aurobindo Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -88.21 - - -

Competitive Comparison of Aurobindo Pharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's EV-to-FCF falls into.



Aurobindo Pharma EV-to-FCF Calculation

Aurobindo Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=676844.458/0
=

Aurobindo Pharma's current Enterprise Value is ₹676,844 Mil.
Aurobindo Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aurobindo Pharma  (NSE:AUROPHARMA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Aurobindo Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1168.60/47.250
=24.73

Aurobindo Pharma's share price for today is ₹1168.60.
Aurobindo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹47.250.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Aurobindo Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines